Sonablate to undergo prostate cancer trials in US:
This article was originally published in Clinica
US researchers are to begin a clinical trial of Misonix' high intensity ultrasound (HIFU) treatment for prostate cancer, under an investigational exemption device from the FDA. The company's Sonablate 500 system will be used to treat around 40 patients at two sites. The HIFU technology can destroy deep-seated tissue by rapidly elevating the temperature in a precise focal zone, without affecting the intervening tissue and without ionisation effects, claims the Farmingdale, New York company. The device is currently in phase III US trials for the treatment of benign prostatic hyperplasia.